A number of therapies from a range of drug classes are available to treat the symptoms of narcolepsy (e.g., excessive daytime sleepiness, cataplexy). Our Treatment Algorithms research leverages national patient-level claims data to explore the use of key therapies for narcolepsy, such as modafinil, armodafinil, and Xyrem, in both newly diagnosed and recently treated patients. These data provide important information regarding the patient journey in narcolepsy, including treatment duration, switch patterns, and persistence and compliance by drug.
- What patient share do key therapies and brands garner by line of therapy in newly diagnosed narcolepsy patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed narcolepsy patients?
- Where has Xyrem been integrated into the treatment algorithm?
- What proportion of narcolepsy patients receive drug therapy within a year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within four years of diagnosis?
- What percentage of narcolepsy patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
- What are the product-level compliance and persistency rates among drug-treated patients with narcolepsy?
Treatment Algorithms: Claims Data Analysis: Provides detailed analysis of brand use across different lines of therapy using real-world patient-level claims data so that clients can accurately assess their source of business and quantify areas of opportunity to increase their brand share.
Markets covered: United States
Real-world data: Longitudinal patient-level claims data analysis
Key companies: Teva, Jazz Pharmaceuticals, Shire, Pfizer, Eli Lilly
Key drugs: Xyrem, Vyvanse, armodafinil (Nuvigil, generics), modafinil (Provigil, generics), atomoxetine (Strattera, generics)
Key analysis provided:
- Brand use across longitudinal patient sample.
- Newly diagnosed patient analysis.
- Treatment initiation and progression.
- Line of therapy analysis.
- Combination therapy analysis.
- Source of business for recently treated patients.
- Persistency and compliance analysis.
- Product-level patient flowcharts.